Non-melanoma skin cancer refers to a group of cancers that slowly develop in the upper layers of the skin. The term non-melanoma distinguishes these more common types of skin cancer from the less common skin cancer known as melanoma, which can be more serious.
Is non-melanoma skin cancer deadly?
Survival for most non-melanoma skin cancers is excellent. The 5-year relative survival for BCC is 100%. This means that, on average, all of the people diagnosed with BCC are just as likely to live at least 5 years after their diagnosis as people in the general population.
Is non-melanoma skin cancer benign?
Most skin tumors are benign (not cancerous) and rarely if ever turn into cancers. There are many kinds of benign skin tumors, including: Most types of moles (see Melanoma Skin Cancer for more about moles)
What are the two most common types of non-melanoma skin cancers?
There are 2 main types of non-melanoma skin cancer – basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
What does non-melanoma look like?
pale white or yellow flat areas that look like scars. raised and scaly red patches. small, smooth and shiny lumps that are pearly white, pink or red. a pink growth with raised edges and indents in the centre.
Does non-melanoma skin cancer spread?
Cancer cells can spread from the skin to other parts of the body. This spread is called metastasis. But most non-melanoma skin cancers do not spread to other parts of the body.
What skin cancer is worse than melanoma?
Merkel cell carcinoma (MCC) is 40 times more rare than melanoma, with an estimated one case per 130,000 people in the U.S.
How long does it take for actinic keratosis to become cancerous?
In summary, of the estimated 10% of AKs that will develop into an SCC, the progression will take approximately 2 years.
Which type of skin cancer is the most common?
Basal and squamous cell carcinomas are the two most common types of skin cancer. They begin in the basal and squamous layers of the skin, respectively. Melanoma, the third most common type of skin cancer, begins in the melanocytes.